Skip to main content

Table 5 Results in perspective (adapted from [24])

From: Ramipril-based versus diuretic-based antihypertensive primary treatment in patients with pre-diabetes (ADaPT) study

  RAS blocking agent Control Number of patients Follow-up RR (95%CI)
SOLVD [36] Enalapril Placebo 4,228 3.4 0.26 (0.13-0.53)
AASK [30] Ramipril Betablocker/
Amlodipine
1,094 4.1 0.64 (0.45-0.90)
HOPE [31] Ramipril Placebo 9,297 5 0.67 (0.52-0.85)
ANBP2 [37, 38] Enalapril Diuretic 6,083 4.1 0.70 (0.56-0.86)
ALLHAT [39] Lisinopril Chlorthalidone/Amlodipine 33,357 4.9 0.75 (0.59-0.94)
IMAGINE [40] Quinapril Placebo 2,553 2.95 0.79 (0.48-1.29)
ADaPT [22] Ramipril Betablockers/
Diuretic
2,011 3 0.83 (0.65-0.80)
PEACE [41] Trandolapril Placebo 8,290 4.8 0.85 (0.74-0.97)
CAPPP [42] Captopril Betablockers/
Diuretic
10,985 6.1 0.89 (0.78-1.03)
DREAM [1, 32] Ramipril Placebo 5,269 3 0.93 (0.82-1.04)
STOP-2 [43] Enalapril/
Lisinopril
Betablockers/
Diuretic
6,614 5 0.95 (0.72-1.26)
ALPINE [44] Candesartan HCTZ 392 1 0.13 (0.02-0.99)
CASE-J [45] Candesartan Amlodipine 4,703 3.2 0.65 (0.44-0.98)
LIFE [46] Losartan Atenolol 9,193 4.8 0.75 (0.64-0.88)
CHARM [47] Candesartan Placebo 7,599 3.2 0.81 (0.66-0.99)
SCOPE [48] Candesartan Placebo 4,937 3.7 0.81 (0.62-1.06)
VALUE [16] Valsartan Amlodipine 15,245 4.2 0.81 (0.74-0.89)
PRoFESS [49] Telmisartan Placebo 20,332 2.5 0.83 (0.65-1.04)
TRANSCEND [50] Telmisartan Placebo 5,926 4.6 0.86 (0.72-1.02)
NAVIGATOR [17] Valsartan Placeno 9,306 5 0.86 (0.80-0.92)
  1. Legend. RR, relative risk; HCTZ, hydrochlorothiazide